These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5621 related articles for article (PubMed ID: 21369647)
1. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. Gottlieb AB; Gordon K; Giannini EH; Mease P; Li J; Chon Y; Maddox J; Weng HH; Wajdula J; Lin SL; Baumgartner SW J Drugs Dermatol; 2011 Mar; 10(3):289-300. PubMed ID: 21369647 [TBL] [Abstract][Full Text] [Related]
2. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. Pariser DM; Leonardi CL; Gordon K; Gottlieb AB; Tyring S; Papp KA; Li J; Baumgartner SW J Am Acad Dermatol; 2012 Aug; 67(2):245-56. PubMed ID: 22015149 [TBL] [Abstract][Full Text] [Related]
3. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328 [TBL] [Abstract][Full Text] [Related]
4. Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis. van der Heijde D; Zack D; Wajdula J; Sridharan S; Koenig AS Scand J Rheumatol; 2014; 43(1):49-53. PubMed ID: 24182312 [TBL] [Abstract][Full Text] [Related]
5. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. Moreland LW; Weinblatt ME; Keystone EC; Kremer JM; Martin RW; Schiff MH; Whitmore JB; White BW J Rheumatol; 2006 May; 33(5):854-61. PubMed ID: 16541481 [TBL] [Abstract][Full Text] [Related]
6. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. Aggarwal R; Manadan AM; Poliyedath A; Sequeira W; Block JA J Rheumatol; 2009 May; 36(5):914-7. PubMed ID: 19332623 [TBL] [Abstract][Full Text] [Related]
7. Etanercept: new indication. For ankylosing spondylitis: another option. Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387 [TBL] [Abstract][Full Text] [Related]
8. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Lebwohl M; Blum R; Berkowitz E; Kim D; Zitnik R; Osteen C; Wallis WJ Arch Dermatol; 2005 Jul; 141(7):861-4. PubMed ID: 16027301 [TBL] [Abstract][Full Text] [Related]
10. Etanercept: efficacy and safety for approved indications. Kerensky TA; Gottlieb AB; Yaniv S; Au SC Expert Opin Drug Saf; 2012 Jan; 11(1):121-39. PubMed ID: 22074366 [TBL] [Abstract][Full Text] [Related]
11. Etanercept: an evolving role in psoriasis and psoriatic arthritis. Prodanovich S; Ricotti C; Glick BP; Inverardi L; Leonardi CL; Kerdel F Am J Clin Dermatol; 2010; 11 Suppl 1():3-9. PubMed ID: 20586498 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis. Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386 [TBL] [Abstract][Full Text] [Related]
13. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. Gottlieb AB; Leonardi CL; Goffe BS; Ortonne JP; van der Kerkhof PC; Zitnik R; Nakanishi A; Jahreis A J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S92-100. PubMed ID: 16488335 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Lovell DJ; Reiff A; Ilowite NT; Wallace CA; Chon Y; Lin SL; Baumgartner SW; Giannini EH; Arthritis Rheum; 2008 May; 58(5):1496-504. PubMed ID: 18438876 [TBL] [Abstract][Full Text] [Related]
15. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. Papp KA; Poulin Y; Bissonnette R; Bourcier M; Toth D; Rosoph L; Poulin-Costello M; Setterfield M; Syrotuik J J Am Acad Dermatol; 2012 Feb; 66(2):e33-45. PubMed ID: 20850895 [TBL] [Abstract][Full Text] [Related]
16. Etanercept: new preparation. Useful after methotrexate failure in inflammatory rheumatism. Prescrire Int; 2003 Aug; 12(66):127-32. PubMed ID: 12906020 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Davis JC; van der Heijde DM; Braun J; Dougados M; Clegg DO; Kivitz AJ; Fleischmann RM; Inman RD; Ni L; Lin SL; Tsuji WH Ann Rheum Dis; 2008 Mar; 67(3):346-52. PubMed ID: 17967833 [TBL] [Abstract][Full Text] [Related]
19. Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept. van Luijn JC; Danz M; Bijlsma JW; Gribnau FW; Leufkens HG Scand J Rheumatol; 2011 May; 40(3):183-91. PubMed ID: 20858147 [TBL] [Abstract][Full Text] [Related]
20. Managing pediatric patients with psoriasis. Bard S; Torchia D; Schachner LA Am J Clin Dermatol; 2010; 11 Suppl 1():15-7. PubMed ID: 20586500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]